Additional Local Consolidative Therapy Showed Survival Benefit Than EGFR-TKIs Alone in Bone Oligometastatic Lung Adenocarcinoma Patients

被引：0
|
作者：
Hu, F. [1 ]
Li, C. [1 ]
Xu, J. [1 ]
Guo, J. [1 ]
Shen, Y. [1 ]
Nie, W. [1 ]
Zheng, X. [1 ]
Wang, L. [2 ]
Zhang, H. [1 ]
Han, B. [1 ]
Zhang, X. [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai, Peoples R China
[2] Tongji Univ, Shanghai Pulm Hosp, Integrated Tem & Western Med Dept, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Bone oligometastases; Local consolidative therapy; Epidermal growth factor receptor mutation;
D O I：
10.1016/j.jtho.2019.08.500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA01.10
引用
收藏
页码：S251 / S251
页数：1
相关论文
共 50 条
  • [21] EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases
    Jiang, Tao
    Su, Chunxia
    Li, Xuefei
    Zhao, Chao
    Zhou, Fei
    Ren, Shengxiang
    Zhou, Caicun
    Zhang, Jun
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : 1718 - 1728
  • [22] EGFR Mutations Predict Superior Survival of NSCLC Patients with Oligometastatic Disease Treated with Local Consolidative Therapy
    Farooqi, A.
    Mitchell, K.
    Ludmir, E.
    Boyce-Fappiano, D.
    Vaporciyan, A.
    Swisher, S.
    Zhang, J.
    Le, X.
    Antonoff, M.
    Gomez, D.
    Elamin, Y.
    Heymach, J.
    Gandhi, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S198 - S198
  • [23] Leukocyte telomere length is associated with survival and drug resistance in lung adenocarcinoma patients treated with EGFR-TKIs
    Yang, M.
    Li, J.
    Zhang, N.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] The Functional MDM4 Genetic Polymorphsim as Prognostic Biomarker for Advanced Lung Adenocarcinoma Patients' Survival to EGFR-TKIs Therapy
    Yang, M.
    Zhang, N.
    Xing, H.
    Liu, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S593 - S593
  • [25] Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy>
    Hung, Ming-Szu
    Chuang, Min-Chun
    Tsai, Ying-Huang
    Yang, Yao-Hsu
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [26] Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
    Lin, Jessica J.
    Cardarella, Stephanie
    Lydon, Christine A.
    Dahlberg, Suzanne E.
    Jackman, David M.
    Jaenne, Pasi A.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : 556 - 565
  • [27] Leukocyte telomere length and recurrence risk after EGFR-TKIs therapy in patients with advanced lung adenocarcinoma
    Yang, M.
    Li, J.
    Zhang, N.
    Xing, H.
    Liu, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [28] Addition of Local Therapy to EGFR TKI Showed Survival Benefit in EGFR-Mutant NSCLC pts with Oligometastatic or Oligoprogressive Liver Metastases
    Jiang, T.
    Zhou, C.
    Wang, H.
    Chu, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S336 - S336
  • [29] Compared with the difference in efficacy between EGFR-TKIs alone and EGFR-TKIs combined with craniocerebral radiotherapy in EGFR mutant lung adenocarcinoma patients with brain metastasis. A propensity-score matched analysis
    Deng, G.
    Li, Z.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1012 - S1012
  • [30] The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
    Hung, Ming-Szu
    Lung, Jr-Hau
    Lin, Yu-Ching
    Fang, Yu-Hung
    Hsieh, Meng-Jer
    Tsai, Ying-Huang
    MEDICINE, 2016, 95 (26)
12345